This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
SUFU · Western blot design guide
SUFU Western Blot Planning Guide
Plan a SUFU Western blot around the catalog-observed 53.9 kDa band, image-backed A02279-1 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
SUFU Western Blot Experimental Design Guide
Expected bands, documented protocol parameters, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 53.9 kDa | |
| Observed band | Not reported — verify product WB image | |
| Gel | 12-15% | |
| Positive control | Cervix | |
| Negative control | Spleen |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 53.9 kDa |
| ⓘ | Localization | Cytoplasm / Nucleus |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human / Mouse / Rat |
Section 1
Real Curated SUFU Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Adrenal gland |
| Gel % | 12-15% |
| Load | 20-30 µg total protein per lane |
| Transfer | Semi-dry, standard transfer |
| Membrane | 0.45 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | A02279-1 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 2
What Is the Expected SUFU Western Blot Band Size?
Use the product-observed 53.9 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 53.9 kDa | Matches the authoritative product WB observation. |
| 53.9 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected SUFU appearancePlan around 53.9 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 53.9 kDa; use this as the primary experimental expectation. |
| Calculated mass | 53.9 kDa from UniProt Q9UMX1; retain as context. |
| Gel selection | 12-15%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with A02279-1. |
| Situation | Likely cause | Next action |
|---|---|---|
| 53.9 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing SUFU band
A02279-1 · SUFU
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for SUFU Western blot
🧪Use Cervix as the first positive-control candidate and Spleen as the HPA Not detected negative candidate.
Positive control: Cervix (High)
Negative control: Spleen (Not detected)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for SUFU
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Cervix | Reported tissue cells | High | Protein (HPA) | HPA → |
| Cerebellum | Reported tissue cells | High | Protein (HPA) | HPA → |
| Breast | Reported tissue cells | High | Protein (HPA) | HPA → |
| Adrenal gland | Reported tissue cells | High | Protein (HPA) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Spleen | Reported tissue cells | Not detected | Protein (HPA) | HPA → |
Section 3
Advanced SUFU Western Blot Tips
Deeper troubleshooting and optimisation questions for SUFU, answered from its protein features.
Which band should guide the blot?
Use 53.9 kDa, the observation attached to the authoritative A02279-1 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 53.9 kDa expectation.
Which positive control should I start with?
Start with Cervix, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Spleen as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 12-15% consistently across the quick facts, protocol table, and poster.
What transfer method to use for SUFU Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should A02279-1 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents
SUFU Western Blot Reagents
Human/Mouse/Rat-reactive SUFU Western blot reagents with authoritative product imagery.
Real WB data
Anti-SUFU Picoband® Antibody
Cat # A02279-1
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt Q9UMX1
- Human Protein Atlas — SUFU
- A02279-1 product record
- PMC3362617 — Novel mechanism of action on Hedgehog signaling by a suppressor of fused carboxy terminal variant (PloS one, 2012)
- PMC8140158 — SPOP-PTEN-SUFU axis promotes progression of clear cell renal cell carcinoma via activating SHH and WNT pathway (Cell death discovery, 2021)
- PMC12968324 — CMA-mediated USP9X degradation promotes SHH medulloblastoma progression by facilitating SUFU ubiquitination (Clinical and translational medicine, 2026)